ACRS ACLARIS THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ACLARIS THERAPEUTICS INC reported revenue of $1.63M (down 8.3% from a year earlier), net income of −$21.5M and diluted EPS of −$0.15; over the last four quarters revenue was $8.22M and net income −$75.7M; for the fiscal year ended December 2025 revenue was $7.83M, down 58.2% on the year before.

ACRS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $7.83M, gross profit n/a, operating income −$76.4M, net income −$64.9M (margin -829.6%), EPS −$0.53
• Fiscal year ended Dec 2024: revenue $18.7M, gross profit n/a, operating income −$142M, net income −$132M (margin -705.5%), EPS −$1.71
• Fiscal year ended Dec 2023: revenue $31.2M, gross profit n/a, operating income −$97.4M, net income −$88.5M (margin -283.1%), EPS −$1.27
• Fiscal year ended Dec 2022: revenue $29.8M, gross profit n/a, operating income −$89.9M, net income −$86.9M (margin -292.1%), EPS −$1.33
• Fiscal year ended Dec 2021: revenue $6.76M, gross profit n/a, operating income −$89.7M, net income −$90.9M (margin -1344.0%), EPS −$1.60

ACRS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.63M (down 8.3% year over year), net income −$21.5M, EPS −$0.15
• Quarter ended Mar 31, 2026: revenue $2.00M (up 37.2% year over year), net income −$19.8M, EPS −$0.15
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.30M (down 85.9% year over year), net income −$19.8M, EPS −$0.16
• Quarter ended Sep 30, 2025: revenue $3.30M (down 24.1% year over year), net income −$14.6M, EPS −$0.12
• Quarter ended Jun 30, 2025: revenue $1.78M (down 35.8% year over year), net income −$15.4M, EPS −$0.13
• Quarter ended Mar 31, 2025: revenue $1.46M (down 39.3% year over year), net income −$15.1M, EPS −$0.12
• Quarter ended Dec 31, 2024 (from the annual report): revenue $9.21M (down 47.6% year over year), net income −$96.6M, EPS −$1.21
• Quarter ended Sep 30, 2024: revenue $4.35M (down 53.2% year over year), net income −$7.59M, EPS −$0.11
• Quarter ended Jun 30, 2024: revenue $2.77M (up 48.0% year over year), net income −$11.0M, EPS −$0.15
• Quarter ended Mar 31, 2024: revenue $2.40M (down 5.1% year over year), net income −$16.9M, EPS −$0.24
• Quarter ended Dec 31, 2023 (from the annual report): revenue $17.6M (up 126.6% year over year), net income −$1.49M, EPS −$0.02
• Quarter ended Sep 30, 2023: revenue $9.28M (down 51.2% year over year), net income −$29.3M, EPS −$0.41
• Quarter ended Jun 30, 2023: revenue $1.87M (up 22.3% year over year), net income −$29.6M, EPS −$0.42
• Quarter ended Mar 31, 2023: revenue $2.53M (up 74.0% year over year), net income −$28.2M, EPS −$0.42
• Quarter ended Dec 31, 2022 (from the annual report): revenue $7.75M (up 416.5% year over year), net income −$27.6M, EPS −$0.41
• Quarter ended Sep 30, 2022: revenue $19.0M (up 1046.4% year over year), net income −$20.0M, EPS −$0.30
• Quarter ended Jun 30, 2022: revenue $1.53M (down 16.2% year over year), net income −$20.5M, EPS −$0.31
• Quarter ended Mar 31, 2022: revenue $1.45M (down 18.2% year over year), net income −$18.8M, EPS −$0.31
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.50M, net income −$22.8M, EPS −$0.34
• Quarter ended Sep 30, 2021: revenue $1.66M, net income −$21.1M, EPS −$0.35

ACRS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$47.1M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$20.1M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$78.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$67.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$52.1M, share buybacks n/a

ACRS balance sheet

• Jun 30, 2026: cash $19.2M, total assets $180M, total liabilities $55.1M, shareholders' equity $125M
• Mar 31, 2026: cash $28.7M, total assets $199M, total liabilities $55.1M, shareholders' equity $144M
• Dec 31, 2025: cash $20.0M, total assets $160M, total liabilities $57.4M, shareholders' equity $103M
• Sep 30, 2025: cash $25.3M, total assets $176M, total liabilities $55.4M, shareholders' equity $120M
• Jun 30, 2025: cash $25.4M, total assets $189M, total liabilities $57.4M, shareholders' equity $132M
• Mar 31, 2025: cash $30.4M, total assets $198M, total liabilities $54.0M, shareholders' equity $144M
• Dec 31, 2024: cash $24.6M, total assets $220M, total liabilities $64.8M, shareholders' equity $156M
• Sep 30, 2024: cash $47.7M, total assets $182M, total liabilities $52.2M, shareholders' equity $130M

What is ACRS's revenue?

ACLARIS THERAPEUTICS INC reported $8.22M of revenue over its last four quarters, through June 30, 2026.

Is ACRS profitable?

No. ACLARIS THERAPEUTICS INC lost $75.7M over the last four quarters.

What is ACRS's EPS?

Diluted earnings per share over the last four quarters were −$0.58; −$0.15 in the latest quarter.

ACRS ownership and insider trades · All stocks